Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPEPPS | P55786 | 6/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280364 | 0.92 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12281159 | 0.92 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12280869 | 0.89 | AHCY (0.35) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12280575 | 0.87 | LMNA (0.44) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL29567177 | 0.82 | PDPK1 (0.34) | — | |
| SCHEMBL18571623 | 0.81 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL22776099 | 0.79 | PDPK1 (0.31) | — | |
| SCHEMBL18512601 | 0.79 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL864471 | 0.78 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL22787607 | 0.78 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| WO-2010036213-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | PI4KA 1765/4885PI4K2B 1727/4885PI4K2A 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.